(Albany, US) DelveInsight has launched a new report on Advanced Renal Cell Carcinoma Pipeline
“Advanced Renal Cell Carcinoma (RCC) Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Advanced Renal Cell Carcinoma (RCC) market. A detailed picture of the Advanced Renal Cell Carcinoma (RCC) pipeline landscape is provided, which includes the disease overview and Advanced Renal Cell Carcinoma (RCC) treatment guidelines. The assessment part of the report embraces in-depth Advanced Renal Cell Carcinoma (RCC) commercial assessment and clinical assessment of the Advanced Renal Cell Carcinoma (RCC) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma (RCC) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Renal cell carcinoma (RCC), also called renal cell cancer or renal cell adenocarcinoma, which comprises almost all type of kidney cancers. RCC usually begins as a tumor growing in one of the kidneys, which can easily develop in both the kidneys, at times it can also be advanced or metastatic that can easily spread to the other parts of the body. The tumor can invade a large vein leading out of the kidney. It can also spread to the lymph system and other organs (lungs being the most vulnerable).
Request for free sample page: – https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight
Advanced Renal Cell Carcinoma (RCC) of pipeline development activities
The report provides insights into:
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Advanced Renal Cell Carcinoma Pipeline
Advanced Renal Cell Carcinoma pipeline possesses potential drugs in late and mid-stage developments to be launched in the near future.
Atezolizumab + Bevacizumab (Merck and Genentech), combination is being investigated for advanced RCC in phase III stage of clinical development. Atezolizumab binds to a protein called PD-L1, which is found on cancer cells and blocks this protein thereby helping the immune system in killing the cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Bevacizumab is a tumor-starving (anti-angiogenic) therapy which is designed to block a protein called vascular endothelial growth factor, or VEGF. Normal cells make VEGF, but some cancer cells, especially kidney cancer cells, make too much VEGF.
Pembrolizumab + Lenvatinib (Merck/Eisai), the combination is being investigated in phase III stage of clinical development by the prominent key players for the patients with advanced RCC. In May 2020, phase II trial of Pembrolizumab + Lenvatinib for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma were presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program 2020.
Marketed drugs included in the report
· Keytruda/Inlyta: Merck/Pfizer
· Opdivo/Yervoy: Bristol-Myers Squibb
· Bavencio/Inlyta: Merck/Pfizer
· Lenvima/Afinitor: Eisai/Novartis
· Sutent: Pfizer
· Cabometyx: Exelixis
· Avastin: Genentech (Roche)
· Votrient: Novartis
· Fotivda: AVEO Oncology
Emerging drugs included in the report
Advanced Renal Cell Carcinoma Report Scope
Download free sample page:- https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight
Table of content
1. Report Introduction
2. Advanced Renal Cell Carcinoma (RCC)
3. Advanced Renal Cell Carcinoma (RCC) Current Treatment Patterns
4. Advanced Renal Cell Carcinoma (RCC) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Advanced Renal Cell Carcinoma (RCC) Late Stage Products (Phase-III)
7. Advanced Renal Cell Carcinoma (RCC) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Advanced Renal Cell Carcinoma (RCC) Discontinued Products
13. Advanced Renal Cell Carcinoma (RCC) Product Profiles
14. Advanced Renal Cell Carcinoma (RCC) Key Companies
15. Advanced Renal Cell Carcinoma (RCC) Key Products
16. Dormant and Discontinued Products
17. Advanced Renal Cell Carcinoma (RCC) Unmet Needs
18. Advanced Renal Cell Carcinoma (RCC) Future Perspectives
19. Advanced Renal Cell Carcinoma (RCC) Analyst Review
20. Appendix
21. Report Methodology
Related Reports
Advanced Renal Cell Carcinoma (RCC) – Market Insights, Epidemiology and Market Forecast – 2030
Advanced Renal Cell Carcinoma (RCC) – Epidemiology Forecast 2030
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/